Corat Therapeutics specializes in the development of innovative therapeutic drugs utilizing fully human recombinant antibodies to combat COVID-19. Their lead product, COR-101, is designed to neutralize the SARS-CoV-2 virus effectively, demonstrating a remarkable ability to reduce viral load in preclinical models. The company employs a sophisticated antibody phage display technique to isolate over 700 unique human monoclonal antibodies from both healthy donors and convalescent COVID-19 patients. This process allows them to identify candidates that specifically target various epitopes of the SARS-CoV-2 spike protein, leading to the selection of optimal drug candidates for further development. The antibodies are engineered with silencing modifications to prevent unwanted immune responses, making them suitable for patients with active immune systems.

The therapeutic approach taken by Corat Therapeutics is distinct from traditional vaccines, as their antibodies provide immediate protection and therapeutic effects for individuals already infected with the virus. Unlike vaccines, which require weeks to induce an immune response, CORAT antibodies can lower viral burdens almost instantly upon administration. This passive immunization strategy is particularly beneficial for vulnerable populations, including healthcare workers and individuals with underlying health conditions. The safety and efficacy of these fully human antibodies are supported by extensive preclinical studies, and they are expected to complement existing vaccination efforts by addressing the treatment needs of those who cannot mount an adequate immune response.

Germany

CORAT develops phage-display derived fully human antibodies into passive vaccines to treat and to protect against COVID-19

Corat Therapeutics

Company Details